Andrea Svoboda, NP
Family · Youngstown, OHNPI 1265989016
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $83,020 of the $90,718 with a category attached, or 91.5%. 29 manufacturers reported payments, led by AbbVie at 48.0% of the total. Reporting peaked in 2021 at $41,038 and has fallen 84.9% since, to $6,197 in 2025. Among family clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 297 payments — averaging $305.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$44K
- Biohaven Pharmaceutical Holding Company Ltd.$21K
- Biohaven Pharmaceuticals, Inc.$21K
- Pfizer$2K
- AstraZeneca$485
- Amgen$300
- plus $2K from 23 others
What the payments were for
- Consulting fees$6751%
- Speaking & faculty fees$83,02092%
- Travel & lodging$1670%
- Food & beverage$6,8037%
- Education$530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 145 | $43,570 |
| Biohaven Pharmaceutical Holding Company Ltd. | 39 | $21,133 |
| Biohaven Pharmaceuticals, Inc. | 35 | $20,845 |
| Pfizer | 19 | $2,469 |
| AstraZeneca(2 entities) | 9 | $485 |
| Amgen | 9 | $300 |
| Novo Nordisk | 2 | $244 |
| GSK | 2 | $182 |
| Biogen | 8 | $150 |
| Jazz Pharmaceuticals Inc. | 1 | $148 |
| Lundbeck LLC | 2 | $143 |
| Abbott | 1 | $136 |
| Sanofi | 1 | $135 |
| E.r. Squibb & Sons, L.L.C. | 1 | $111 |
| SK Life Science, Inc. | 2 | $107 |
| Eisai Inc. | 1 | $90 |
| Teva Pharmaceuticals USA, Inc. | 2 | $84 |
| Argenx US, Inc. | 1 | $70 |
| Cala Health, Inc. | 2 | $59 |
| Bristol Myers Squibb | 1 | $53 |
| Genentech USA, Inc. | 2 | $41 |
| Medtronic | 1 | $33 |
| Impel Pharmaceuticals Inc. | 2 | $29 |
| Sunovion Pharmaceuticals Inc. | 4 | $25 |
| Lilly USA, LLC | 1 | $18 |
| Banner Life Sciences, LLC | 1 | $17 |
| Novartis | 1 | $15 |
| Neurelis, Inc. | 1 | $13 |
| GE HealthCare | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$43,119
- UBRELVY$36,993
- QULIPTA$12,330
- DUPIXENT$270
- AIMOVIG$180
- Epidiolex$148
- AMPLATZER TALISMAN$136
- TRELEGY ELLIPTA$125
- LOKELMA$124
- SOLIRIS$123
- Saxenda$123
- VYEPTI$122
- Wegovy$122
- Creon$119
- ZEPOSIA$111
How this compares
$90,718 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 87 | $95,401 |
| UbrelvyUbrogepant | 66 | $87,925 |
| QuliptaAtogepant | 57 | $84,866 |
| NuplazidPimavanserin Tartrate | 12 | $60,249 |
| AptiomEslicarbazepine Acetate | 38 | $43,649 |
| Aimovig AutoinjectorErenumab-Aooe | 32 | $39,955 |
| VimpatLacosamide | 26 | $39,642 |
| Emgality PenGalcanezumab-Gnlm | 31 | $34,544 |
| NuedextaDextromethorphan Hbr/Quinidine | 20 | $28,480 |
| Topiramate ErTopiramate | 21 | $15,777 |
| Levetiracetam | 289 | $10,597 |
| Lacosamide | 64 | $7,393 |
| Sumatriptan Succinate | 49 | $7,161 |
| Memantine Hcl | 35 | $4,794 |
| Gabapentin | 150 | $3,928 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $43,570 | $172,791123 claims |
| PfizerNurtec Odt | $2,469 | $95,40187 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $25 | $43,64938 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.
Other family in Youngstown
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
- Florence StewartNew Albany$113K
- Kirt MunsonToledo$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.